The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1686
ISSUE1686
October 2, 2023
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
October 2, 2023 (Issue: 1686)
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.